Denmark-headquartered pharmaceutical company Orifarm has agreed to divest a portfolio of 16 vitamins, minerals and supplements (VMS) brands to Stada as part of a strategic move to concentrate on its pharmaceutical operations.

The transaction marks a portfolio realignment for Orifarm, which said the sale supports its long-term focus on prescription medicines, over-the-counter medicines, parallel-traded products and niche generics across European markets.

According to Investors in Healthcare, the brands included in the agreement operate across multiple countries and include established pharmacy and consumer health products in Norway, Denmark, Belgium and Poland.

Orifarm stated that the divestment allows the business to direct greater attention towards its core pharmaceutical activities and its objective of supporting access to medicines across Europe.

For Stada, the acquisition aligns with its broader consumer healthcare strategy centred on established regional and national brands. The company indicated that the portfolio will be integrated into its existing consumer healthcare activities with plans to support future product development and commercial expansion.

The agreement is also notable as one of the first transactions announced following changes to Stada’s ownership structure after private equity investor CapVest agreed to acquire a majority stake in the company in 2025.

The transaction highlights continued portfolio specialisation across the pharmaceutical sector, where companies are increasingly refining business structures around distinct growth areas rather than maintaining broader healthcare portfolios.

For manufacturers operating across pharmaceuticals and consumer health categories, targeted divestments continue to be used to strengthen operational focus, allocate capital more selectively and reinforce long-term positioning within core therapeutic and medicines markets.

Financial terms of the VMS portfolio transaction were not disclosed.